{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:51:46Z","timestamp":1791258706986,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01560-5","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:44:51Z","timestamp":1783788291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-1206","authenticated-orcid":false,"given":"Giuseppe G.","family":"Loscocco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Aperna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moazah","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyansh","family":"Faldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-085X","authenticated-orcid":false,"given":"Masooma S.","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amritpal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-6327","authenticated-orcid":false,"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"1560_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u20131228.","journal-title":"Blood"},{"key":"1560_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u20131719.","journal-title":"Leukemia"},{"key":"1560_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737159.2025.2573466","volume":"25","author":"GG Loscocco","year":"2025","unstructured":"Loscocco GG, Gangat N, Guglielmelli P, Vannucchi AM, Tefferi A. Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models. Expert Rev Mol Diagn. 2025;25:775\u2013792.","journal-title":"Expert Rev Mol Diagn"},{"key":"1560_CR4","doi-asserted-by":"publisher","unstructured":"Tefferi A, Vannucchi AM, Barbui T Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 2021. https:\/\/doi.org\/10.1038\/s41375-021-01401-3.","DOI":"10.1038\/s41375-021-01401-3"},{"key":"1560_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jama.2024.25349","volume":"333","author":"A Tefferi","year":"2025","unstructured":"Tefferi A, Gangat N, Loscocco GG, Guglielmelli P, Szuber N, Pardanani A, et al. Essential thrombocythemia. JAMA. 2025;333:701.","journal-title":"JAMA"},{"key":"1560_CR6","doi-asserted-by":"publisher","first-page":"E464","DOI":"10.1002\/ajh.26377","volume":"96","author":"CJ Smith","year":"2021","unstructured":"Smith CJ, Thomas JW, Ruan G, Hyun MC, Bansal R, McLaughlin N, et al. A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. Am J Hematol. 2021;96:E464\u2013E468.","journal-title":"Am J Hematol"},{"key":"1560_CR7","doi-asserted-by":"publisher","unstructured":"Harrison CN, Barbui T, Bose P, Kiladjian JJ, Mascarenhas J, McMullin MF, et al. Polycythaemia vera. Nat Rev Dis Primers 2025;11. https:\/\/doi.org\/10.1038\/S41572-025-00608-3.","DOI":"10.1038\/S41572-025-00608-3"},{"key":"1560_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","volume":"99","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99:697\u2013718.","journal-title":"Am J Hematol"},{"key":"1560_CR9","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","volume":"18","author":"AM Vannucchi","year":"2009","unstructured":"Vannucchi AM, Masala G, Antonioli E, Susini MC, Guglielmelli P, Pieri L, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomark Prev. 2009;18:2068\u20132073.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1560_CR10","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","volume":"118","author":"H Frederiksen","year":"2011","unstructured":"Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, S\u00f8rensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118:6515\u20136520.","journal-title":"Blood"},{"key":"1560_CR11","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1182\/blood-2011-12-401455","volume":"119","author":"MC Susini","year":"2012","unstructured":"Susini MC, Masala G, Antonioli E, Pieri L, Guglielmelli P, Palli D, et al. Risk of second cancers in chronic myeloproliferative neoplasms. Blood. 2012;119:3861\u20133862.","journal-title":"Blood"},{"key":"1560_CR12","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S2352-3026(18)30108-X","volume":"5","author":"S Chattopadhyay","year":"2018","unstructured":"Chattopadhyay S, Zheng G, Sud A, Yu H, Sundquist K, Sundquist J, et al. Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden. Lancet Haematol. 2018;5:e368\u2013e377.","journal-title":"Lancet Haematol"},{"key":"1560_CR13","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","volume":"32","author":"AR Landtblom","year":"2018","unstructured":"Landtblom AR, Bower H, Andersson TML, Dickman PW, Samuelsson J, Bj\u00f6rkholm M, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32:2203\u20132210.","journal-title":"Leukemia"},{"key":"1560_CR14","doi-asserted-by":"publisher","unstructured":"Ghirardi A, Carobbio A, Masciulli A, Barbui T. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. Blood Cancer J. 2018;8. https:\/\/doi.org\/10.1038\/s41408-017-0038-3.","DOI":"10.1038\/s41408-017-0038-3"},{"key":"1560_CR15","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","volume":"33","author":"T Barbui","year":"2019","unstructured":"Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019;33:1996\u20132005.","journal-title":"Leukemia"},{"key":"1560_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12103061","volume":"12","author":"M Brabrand","year":"2020","unstructured":"Brabrand M, Frederiksen H. Risks of solid and lymphoid malignancies in patients with myeloproliferative neoplasms: clinical implications. Cancers (Basel). 2020;12:1\u201318.","journal-title":"Cancers (Basel)"},{"key":"1560_CR17","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/ajh.23243","volume":"87","author":"LM Scott","year":"2012","unstructured":"Scott LM, Rebel VI. JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg? Am J Hematol. 2012;87:1028\u20131036.","journal-title":"Am J Hematol"},{"key":"1560_CR18","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1182\/blood-2014-04-570572","volume":"124","author":"Y Kagoya","year":"2014","unstructured":"Kagoya Y, Yoshimi A, Tsuruta-Kishino T, Arai S, Satoh T, Akira S, et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. Blood. 2014;124:2996\u20133006.","journal-title":"Blood"},{"key":"1560_CR19","doi-asserted-by":"publisher","first-page":"15190","DOI":"10.1073\/pnas.1401873111","volume":"111","author":"E Chen","year":"2014","unstructured":"Chen E, Sook Ahn J, Massie CE, Clynes D, Godfrey AL, Li J, et al. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. Proc Natl Acad Sci USA. 2014;111:15190\u201315195.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1560_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","volume":"85","author":"F Lussana","year":"2017","unstructured":"Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun. 2017;85:58\u201363.","journal-title":"J Autoimmun"},{"key":"1560_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12082100","volume":"12","author":"L Kj\u00e6r","year":"2020","unstructured":"Kj\u00e6r L. Clonal hematopoiesis and mutations of myeloproliferative neoplasms. Cancers (Basel). 2020;12:1\u201321.","journal-title":"Cancers (Basel)"},{"key":"1560_CR22","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3390\/ijms23063177","volume":"23","author":"C Cumbo","year":"2022","unstructured":"Cumbo C, Anelli L, Zagaria A, Coccaro N, Tarantini F, Specchia G, et al. Second cancer onset in myeloproliferative neoplasms: what, when, why? Int J Mol Sci. 2022;23:3177.","journal-title":"Int J Mol Sci"},{"key":"1560_CR23","doi-asserted-by":"publisher","first-page":"9236","DOI":"10.1002\/cam4.5666","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Han Y, Teng G, Du C, Gao S, Yuan W, et al. Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms. Cancer Med. 2023;12:9236\u20139246.","journal-title":"Cancer Med"},{"key":"1560_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.blre.2018.03.007","volume":"32","author":"T Karantanos","year":"2018","unstructured":"Karantanos T, Moliterno AR. The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: opportunities for targeted therapy. Blood Rev. 2018;32:426\u2013432.","journal-title":"Blood Rev"},{"key":"1560_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/sj.bjc.6605264","volume":"101","author":"H Ulmer","year":"2009","unstructured":"Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, Diem G, et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer. 2009;101:1202\u20131206.","journal-title":"Br J Cancer"},{"key":"1560_CR26","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s12276-023-01079-w","volume":"55","author":"M Xiao","year":"2023","unstructured":"Xiao M, Xu J, Wang W, Zhang B, Liu J, Li J, et al. Functional significance of cholesterol metabolism in cancer: from threat to treatment. Exp Mol Med. 2023;55:1982\u20131995.","journal-title":"Exp Mol Med"},{"key":"1560_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","volume":"21","author":"NS Wilcox","year":"2024","unstructured":"Wilcox NS, Amit U, Reibel JB, Berlin E, Howell K, Ky B. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol. 2024;21:617\u2013631.","journal-title":"Nat Rev Cardiol"},{"key":"1560_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1158\/1940-6207.CAPR-25-0058","volume":"18","author":"S Min","year":"2025","unstructured":"Min S, Lee H, Cho S, Jeong SY, Shin A, Kang D. Association of elevated serum triglycerides with colorectal cancer risk: findings from a large-scale perspective cohort of Korean adults. Cancer Prev Res. 2025;18:681\u2013691.","journal-title":"Cancer Prev Res"},{"key":"1560_CR29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s42003-020-01391-5","volume":"3","author":"S Jiang","year":"2020","unstructured":"Jiang S. Tet2 at the interface between cancer and immunity. Commun Biol. 2020;3:667.","journal-title":"Commun Biol"},{"key":"1560_CR30","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/bloodadvances.2022008259","volume":"7","author":"R Wang","year":"2023","unstructured":"Wang R, Shallis RM, Stempel JM, Huntington SF, Zeidan AM, Gore SD, et al. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Adv. 2023;7:734\u2013743.","journal-title":"Blood Adv"},{"key":"1560_CR31","doi-asserted-by":"publisher","unstructured":"Gavini DR, Salvi DJ, Shah PH, Uma D, Lee JH, Hamid P. Non-melanoma skin cancers in patients on hydroxyurea for Philadelphia chromosome-negative myeloproliferative neoplasms: a systematic review. Cureus 2021;13. https:\/\/doi.org\/10.7759\/cureus.16978.","DOI":"10.7759\/cureus.16978"},{"key":"1560_CR32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/ijd.15302","volume":"60","author":"CA Bulte","year":"2021","unstructured":"Bulte CA, Hoegler KM, Kutlu \u00d6, Khachemoune A. Hydroxyurea: a reappraisal of its cutaneous side effects and their management. Int J Dermatol. 2021;60:810\u2013817.","journal-title":"Int J Dermatol"},{"key":"1560_CR33","doi-asserted-by":"publisher","unstructured":"Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, van Akkooi A, Bataille V, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention\u2013Update 2023. Eur J Cancer 2023; 193. https:\/\/doi.org\/10.1016\/j.ejca.2023.113251.","DOI":"10.1016\/j.ejca.2023.113251"},{"key":"1560_CR34","volume":"16","author":"C Iliescu","year":"2024","unstructured":"Iliescu C, Beiu C, Slavu I, Racovi\u021b\u0103 A, Slavu CO. Clinical insights and dermatological recommendations for Non-Melanoma Skin Cancers (NMSCs) in long-term Hydroxyurea (HU) therapy. Cureus. 2024;16:e57133.","journal-title":"Cureus"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01560-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01560-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01560-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:18:08Z","timestamp":1791256688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01560-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1560"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01560-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"171"}}